Lisdexamphetamine for the treatment of methamphetamine withdrawal: Safety and feasibility

Friday, 25 October, 2024 - 10:50 to 12:20

By: Liam Acheson, Krista Siefried (National Centre for Clinical Research on Emerging Drugs, UNSW, Australia), Nadine Ezard (St Vicnent's Hospital Sydney), & Rosemary Hansen (Insight: Centre for alcohol and other drug training and workforce development, Australia)

Description: There is currently no approved treatment for methamphetamine (MA) withdrawal. This video reports on the first pilot clinical trial conducted to determine the feasibility and safety of a tapering dose of a new pharmacotherapeutic option, Lisdexamfetamine, for the treatment of acute MA withdrawal. Lisdexamfetamine was found to be safe and feasible for the treatment of acute MA withdrawal.

Presentation files

Type

Tracks

Part of session